NEW YORK, April 7, 2016 /PRNewswire/ -- SurePure, Inc. (OTCBB: SURP) a global leader in liquid photopurification, announced today that the Company's patented photopurification technology has been used to produce key research samples for an upcoming clinical trial. This trial is expected to demonstrate that SurePure's technology, which enables immune active proteins to remain undamaged, will stimulate greater vaccine response in the elderly. Tamarack Biotics and UC Davis are jointly conducting the clinical trial in California.
Bob Comstock, CEO of Tamarack Biotics stated, "SurePure technology has analytically proven to retain key immune active proteins and we are now eager to test the real-world application of this technology. We expect this double-blinded, placebo-controlled clinical trial will help lead to improved, overall health in the elderly and reduce illness-related healthcare costs. This is vitally important research given our rapidly aging population."
Guy Kebble, CEO of SurePure stated, "This application and the clinical trial reflect the value of the SurePure technology in achieving microbial cleanliness while simultaneously retaining the inherent qualities of the product. We are pleased to be partnering with Tamarack Biotics in this important research."
SurePure is a global leader in liquid photopurification, the green alternative to pasteurization and chemicals. Using its patented 'Turbulator' technology, SurePure systems use UV-C light to purify microbiologically sensitive liquids such as wine, fruit juice and milk. Although designed to deliver food-grade solutions, it can also be harnessed to improve processing liquids such as water, brines and sugar syrup solutions, even animal blood plasma. SurePure's technology offers greater microbiological efficacy than conventional UV systems and is effective for both clear and turbid liquids, a world first. SurePure offers a greener alternative to comparable heat or chemical-based processes and significant process and energy savings. It also provides opportunities for the development of innovative and differentiated products with desired consumer benefits, guaranteed food safety and sound commercial benefits. Go to www.surepureinc.com for more information.
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are those other than historical statements of fact, and can be identified by words such as "believes," "projects," "anticipates," "forecasts," and the like. These statements are based on the Companyʼs estimates, beliefs and assumptions as of the date of this press release and are not a guarantee of any future performance. Forward-looking statements are subject to certain known risks and uncertainties, which are detailed in the Companyʼs periodic filings with the SEC available at www.sec.gov. Management undertakes no obligation to update information contained herein, which is subject to change without notice.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/surepure-technology-instrumental-in-clinical-trial-300247859.html
SOURCE SurePure, Inc.